NEUROCRINE BIOSCIENCES, INC. (NASDAQ:NBIX) Files An 8-K Results of Operations and Financial ConditionItem 2.02
On August3, 2017, Neurocrine Biosciences, Inc. announced its financial results for the second quarter ended June30, 2017. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form8-K.
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
| Item 2.02 | FINANCIAL STATEMENTS AND EXHIBITS. |
|
Exhibit Number |
Description of Exhibit |
| 99.1 | Press Release dated August 3, 2017 |
NEUROCRINE BIOSCIENCES INC ExhibitEX-99.1 2 d409947dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Neurocrine Biosciences Reports Second Quarter 2017 Results – INGREZZA® Net Product Sales of $6.3 Million in Initial Two Months of Commercialization as the First and Only U.S. Food and Drug Administration Approved Product for the Treatment of Tardive Dyskinesia – Partner AbbVie Expected to Submit Elagolix NDA for Endometriosis During the Third Quarter of 2017 and Pay $30 Million Milestone in Fourth Quarter of 2017 – Partner Mitsubishi Tanabe Expected to Initiate Pivotal Trial of INGREZZA in Asia for the Treatment of Tardive Dyskinesia and Pay $15 Million in Milestones during Third Quarter of 2017 – Completed Offering of $517.5 Million Convertible Senior Notes Due 2024 San Diego,…To view the full exhibit click here
About NEUROCRINE BIOSCIENCES, INC. (NASDAQ:NBIX)
Neurocrine Biosciences, Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine-based diseases and disorders. The Company’s two lead late-stage clinical programs are Elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc. (AbbVie), and NBI-98854 (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. The Company focuses on developing NBI-640756 against Essential tremor. Its research and development focuses on addressing diseases and disorders of the central nervous and endocrine systems, which include therapeutic categories ranging from hypothalamic-pituitary-adrenal (HPA) disorders to stress-related disorders and neurological/neuropsychiatric diseases. Its Corticotropin-Releasing Factor (CRF) is a hypothalamic hormone released directly into the hypophyseal portal vasculature.
